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With the increased use of imaging studies, especially high-resolution ultrasonography (US), the number of thy-
roid nodules detected has rapidly increased1,2. While it is crucial not to miss cancers among these detected thy-
roid nodules, it is also critically important to detect and diagnose cancers which may be clinically significant. 
Fine-needle aspiration (FNA) is the standard method used to diagnose thyroid nodules detected on US, and it 
is known to be both accurate and cost-effective3,4. Although there have been several guidelines that recommend 
FNA for thyroid nodules3,5–9, a worldwide consensus on indications for FNA of thyroid nodules has not yet been 
achieved.
Because distant metastases can occur in patients with thyroid cancers larger than 2 cm, all nodules larger 
than 2 cm except simple cysts are recommended for FNA even if they have very few suspicious US features3,6,8,10. 
Also, most guidelines do not recommend FNA for thyroid nodules smaller than 1 cm except in high risk patients 
because most papillary microcarcinomas without unfavorable features have no clear negative outcomes11,12. For 
thyroid nodules 1–2 cm in size, most guidelines suggest FNA based on the size and US features of the thyroid nod-
ule3,5,6,8. The Society of Radiologists in Ultrasound (SRU), the National Comprehensive Cancer Network, and the 
American Thyroid Association use a size cutoff of 1.5 cm according to how suspicious the thyroid nodules appear 
on US;3,5,6,8 however, the guidelines of the American Association of Clinical Endocrinologists/Associazione 
Medici Endocrinologi/European Thyroid Association do not consider a size cutoff of 1.5 cm9. Using a 1.5 cm size 
cutoff along with US features as an indication for FNA can be burdensome in real practice. Taking into account 
that guidelines should be easily applicable in clinical practice, a less complicated subclassification system/algo-
rithm is required to indicate which nodules need FNA. Recently, the diagnostic performances and abilities of six 
major worldwide guidelines to identify aggressive cancers were compared for patients with small thyroid nod-
ules13. Although there were no significant associations between positive findings that indicated FNA and distant 
metastasis, recurrence or persistence, the study power of this previous study was too low to detect significant 
differences. With a population-based cohort, we sought to find an association with distant metastasis or thyroid 
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cancer mortality using a size cutoff of 1.5 cm in patients with small thyroid cancers between 1 cm and 2 cm. We 
hypothesized that among thyroid nodules 1 cm or larger but smaller than 2 cm, nodules 1.5 cm or larger had more 
unfavorable clinical outcomes than ones smaller than 1.5 cm. We thought that our research could help provide 
potential evidence to support the 1.5 cm size cutoff as an indication for FNA.
Results
Patient Characteristics.  Table 1 lists patient demographics and clinical characteristics according to tumor 
size. The significant factors between the tumor size groups (group 1: 1–1.4 cm, group 2: 1.5–1.9 cm) were as 
follows; histologic subtype, extrathyroidal extension, cervical lymph node metastasis, distant metastasis, and 
radiation therapy. The number of patients 55 years or older for group 1 and group 2 were 1653 (22.2%) and 1395 
(20.9%), respectively. The rates of extrathyroidal extension, cervical lymph node metastasis and distant metastasis 
in group 2 were 17.1%, 64.9% and 2.7%, respectively.
The cumulative incidence over the entire follow-up time was significantly different between the tumor size 
subgroups among patients who died of thyroid cancer-related causes (P = 0.02), but was not different among 
patients who died of noncancer causes (P = 0.85).
The most frequent causes of noncancer mortality were heart disease (31.2%), other causes (18.3%), cerebro-
vascular diseases (8.1%), and chronic obstructive pulmonary disease (6.3%). The median follow-up time in group 
1 and group 2 was 105 months (range, 0 to 299 months) and 110 months (range, 0 to 299 months), respectively.
Distant Metastasis.  At univariable analysis, group 2 was associated with increased risk of distant metastasis 
compared to group 1 (OR, 1.65; 95% CI, 1.08 to 1.68; P = 0.008). Other significant risk factors for distant metas-
tasis were male sex, other thyroid carcinoma except papillary or follicular carcinomas, extrathyroidal extension, 
cervical lymph node metastasis, surgery type (no surgery, total thyroidectomy v lobectomy), and radiation ther-
apy. Multivariable analysis showed that group 2 was not significantly associated with the risk of distant metastasis 
compared to group 1 after adjustment for patient demographics and clinical characteristics (adjusted OR, 1.19; 






P ValueNo. (%) No. (%)
Age at diagnosis
 ≥ 55 years 1653 (22.2) 1395 (20.9) 0.06
 < 55 years 5789 (77.8) 5280 (79.1)
Male sex 1314 (17.7) 1198 (18.0) 0.65
Race 0.94
 Black 324 (4.3) 286 (4.3)
 White 6238 (83.8) 5610 (84.0)
 Other 880 (11.8) 779 (11.7)
Histologic subtype < 0.001
 Other 199 (2.7) 248 (3.7)
 Follicular 191 (2.6) 320 (4.8)
 Papillary 7052 (94.8) 6107 (91.5)
Extrathyroidal extension 0.003
 Absent 6308 (84.8) 5533 (82.9)
 Present 1134 (15.2) 1142 (17.1)
Cervical lymph node metastasis < 0.001
 Absent 2930 (39.4) 2345 (35.1)
 Present 4512 (60.6) 4330 (64.9)
Distant metastasis 0.008
 Absent 7291 (98.0) 6494 (97.3)
 Present 151 (2.0) 181 (2.7)
Surgery type 0.27
 Lobectomy 991 (13.3) 828 (12.4)
 No surgery 46 (0.6) 41 (0.6)
 Total thyroidectomy 6405 (86.1) 5806 (87.0)
Radiation therapy < 0.001
 None 3105 (41.7) 2511 (37.6)
 Yes 4337 (58.3) 4164 (62.4)
Death resulting from thyroid cancer 51 (0.7) 73 (1.1) 0.02a
Death resulting from noncancer cause 245 (3.3) 229 (3.4) 0.85a
Table 1.  Patient Demographics and Clinical Characteristics. aP value from Gray’s test.
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We also performed subgroup analyses according to an age cutoff of 55 years to identify groups associated with 
distant metastasis (Table 3). In univariable analysis, group 2 was significantly associated with distant metastasis 
when patients were younger than 55 years (OR, 1.39; 95% CI, 1.08 to 1.78; P = 0.01), but was not significantly 
associated with distant metastasis when patients were 55 years or older (OR, 1.22; 95% CI, 0.77 to 1.93; P = 0.39). 
Multivariable analyses showed that group 2 was not significantly associated with distant metastasis for both 
age groups, for both patients 55 years or older (adjusted OR, 0.88; 95% CI, 0.54 to 1.45; P = 0.62) and patients 
younger than 55 years (adjusted OR, 1.27; 95% CI, 0.99 to 1.63; P = 0.06), after adjustment for patient and tumor 
characteristics.
Competing Risk Analysis.  The cumulative incidence curves are shown in Fig. 1. For thyroid cancer-specific 
mortality, the 5-year cumulative incidences of death for group 1 and group 2 were 0.51% and 0.57%, the 10-year 
cumulative incidences were 0.64% and 1.16%, the 15-year cumulative incidences were 0.69% and 1.51%, and the 
20-year cumulative incidences were 1.07% and 1.61%, respectively. For noncancer deaths, the 5-year cumulative 
incidences of death for group 1 and group 2 were 1.34% and 1.26%, the 10-year cumulative incidences were 3.23% 
and 2.86%, the 15-year cumulative incidences were 5.16% and 4.53%, and the 20-year cumulative incidences were 
6.87% and 8.46%, respectively.
On univariable analysis, the risk of thyroid cancer-related mortality was significantly increased in group 2 than 
in group 1, whereas the risk of noncancer mortality was not significantly associated with both groups (Table 4). 
In patients younger than 55 years, group 2 was not significantly associated with thyroid cancer-specific mortality, 
or noncancer mortality, but it was significantly associated with increased thyroid cancer-specific mortality for 
patients 55 years or older (Table 3).
On multivariable analysis, group 2 did not significantly increase thyroid cancer-related mortality or noncan-
cer mortality (Table 5). Increased thyroid cancer-specific mortality was associated with patient age 55 years or 
older, male sex, cancers other than papillary carcinoma, extrathyroidal extension, cervical lymph node metastasis, 
distant metastasis, and no surgery. Significant risk factors for noncancer mortality were patient age 55 years or 
older, male sex, black race, no surgery, and radiation therapy (Table 5). Group 2 was not significantly associated 
with death resulting from thyroid cancer or noncancer causes on multivariable analyses in both age subgroups 
(Table 3).
Discussion
We found that a tumor size of 1.5 cm or larger in small thyroid nodules was not associated with death resulting 
from thyroid cancer or other noncancer causes and was not associated with distant metastasis on multivariable 
analyses using logistic regression and the subdistributional hazards models. These findings were consistent when 
patients were stratified according to age, with the newly updated cutoff of 55 years in the cancer staging system14. 
Significant differences for age disappeared between the two tumor size groups when a cutoff age of 55 years was 




OR (95% CI) P Value OR (95% CI) P Value
Tumor size (1.5–1.9 cm vs 1–1.4 cm) 1.65 (1.08 to 1.68) 0.008 1.19 (0.95 to 1.49) 0.13
Age (≥ 55 years vs < 55 years) 1.06 (0.82 to 1.38) 0.65 1.05 (0.80 to 1.38) 0.72
Male sex 1.91 (1.50 to 2.44) < 0.001 1.62 (1.26 to 2.08) < 0.001
Race
 Black 0.56 (0.27 to 1.16) 0.12 0.85 (0.41 to 1.78) 0.67
 White 0.91 (0.66 to 1.26) 0.57 1.07 (0.77 to 1.49) 0.70
 Other Ref. 1 Ref. 1
Histologic subtype
 Other 2.11 (1.34 to 3.31) 0.001 2.37 (1.46 to 3.84) < 0.001
 Follicular 0.85 (0.45 to 1.61) 0.62 1.25 (0.65 to 2.40) 0.50
 Papillary Ref. 1 Ref. 1
Extrathyroidal extension (presence 
vs absence) 5.89 (4.73 to 7.35) < 0.001 4.62 (3.68 to 5.80) < 0.001
Cervical lymph node metastasis 
(presence vs absence) 5.38 (3.76 to 7.68) < 0.001 4.49 (3.12 to 6.44) < 0.001
Surgery type
 Lobectomy Ref. 1 Ref. 1
 No surgery 4.13 (1.39 to 12.29) 0.01 5.30 (1.64 to 17.18) 0.006
 Total thyroidectomy 2.21 (1.42 to 3.45) < 0.001 1.52 (0.96 to 2.42) 0.07
Radiation therapy (presence vs 
absence) 2.47 (1.90 to 3.22) < 0.001 1.98 (1.50 to 2.62) < 0.001
Table 2.  Univariable and Multivariable Analyses for Distant Metastasis (N = 14117). OR, odds ratio; CI, 
confidence interval.
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In this study, noncancer causes of death were treated as competing risk rather than censoring or all-cause 
mortality, because deaths due to causes unrelated to thyroid cancer interfere with the ability to observe deaths 
resulting from thyroid cancer. The effects of the covariates on multivariable models differ for each cause of death. 
Therefore, we treated deaths from noncancer causes as competing risk events. Another study using the SEER 
database found that patients with thyroid cancer who did not undergo surgical treatment were observed with a 
smaller 5-year overall survival rate, older age, advanced cancer stage, and more distant metastases; however, this 
study did not explain the reason for these differences because the SEER database does not offer information about 
comorbidities15. Our analysis incorporated competing risks using the COD variable in the SEER database instead 
of comorbidity information to infer the effects of noncancer causes of death. The results of our multivariable 
analysis suggest that patients who do not undergo surgery are at significantly high risk of noncancer mortality. 
The most common cause of noncancer mortality in our study was heart disease. Non-surgical patients might 
not be eligible for surgery because of their comorbidities, and this in turn, affected the occurrence of distant 
metastases and mortalities. We resolved these issues by the multivariable competing risks model which included 
non-surgical patients.
Thyroid cancer is the most common cancer among endocrine tumors and its incidence is increasing rapidly 
throughout the world16–18. The main cause of this increase is the rising number of incidentally detected thyroid 
nodules at imagings with US, computed tomography, and magnetic resonance imaging. Considering that most 
thyroid nodules are benign, it is important to identify and select nodules for which FNA is necessary. Most socie-
ties recommend FNA for nodules 1 cm or larger which also have the respective US features and for nodules 2 cm 
or larger except for those with a simple cyst3,6–8. Since the SRU recommended FNA for thyroid nodules, a size cut-
off of 1.5 cm has been used to decide whether or not to perform FNA in accordance to each society’s US criteria3. 
The cutoff tumor size of 1.5 cm currently suggested by thyroid nodule management guidelines would be accept-
able if cancers 1.5 cm or larger showed poorer clinical outcomes compared to tumors smaller than 1.5 cm. Some 
studies were cited in guidelines for FNA of thyroid nodules to support a size cutoff of 1.5 cm. A long-term study of 
1,355 patients with thyroid cancers demonstrated that tumors smaller than 1.5 cm had lower 30-year recurrence 





OR (95% CI) P Value SDHR (95% CI) P Value SDHR (95% CI) P Value
Univariable analysis
 Age < 55 years 1.39 (1.08 to 1.78) 0.01 1.34 (0.68 to 2.6) 0.40 0.87 (0.64 to 1.19) 0.39
 Age ≥ 55 years 1.22 (0.77 to 1.93) 0.39 1.75 (1.15 to 2.66) 0.01 1.12 (0.90 to 1.39) 0.33
Multivariable analysisa
 Age < 55 years 1.27 (0.99 to 1.63) 0.06 1.09 (0.53 to 2.22) 0.82 0.87 (0.64 to 1.18) 0.37
 Age ≥ 55 years 0.88 (0.54 to 1.45) 0.62 1.47 (0.93 to 2.31) 0.10 1.14 (0.91 to 1.42) 0.27
Table 3. Summary of Relative Risks of Tumor Size (1.5–1.9 cm vs 1–1.4 cm) for Distant Metastasis and 
Competing Causes of Death According to Age Subgroups (N = 14117). OR, odds ratio; CI, confidence 
interval; SDHR, subdistribution hazard ratio. aAdjusted for sex, race, histologic subtype, extrathyroidal 
extension, cervical lymph node metastasis, distant metastasis, surgery type, and radiotherapy.
Figure 1. Cumulative incidences of competing causes of death in patients with thyroid cancer according to 
tumor size. The black line indicates patients who died from thyroid cancer, and the blue line indicates patients 
who died from noncancer causes. Solid line, 1.5–1.9 cm; Dashed line, 1–1.4 cm.
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However, this study included cancers from 0.2 cm to 10 cm in size; thus, there was insufficient evidence to sup-
port using the 1.5 cm cutoff to indicate FNA for nodules 1–2 cm in size, as was suggested by previous guidelines. 
Although multivariable analyses with adjustment for patient and tumor characteristics were performed, tumor 
size was considered as continuous scale. Another study using the SEER database found that the 10-year relative 
survival rates for tumors sized 1.5 cm or larger and tumors less than 1.5 cm were 95.4% and 99.8%, respectively20. 
However, this study included thyroid cancers which were less than 5 mm to thyroid cancers 4 cm or larger; more-
over, no adjustment was made for tumor and treatment characteristics.
Developing appropriate criteria to select which small thyroid nodules should undergo FNA is essential 
to prevent the risk of missing clinically significant cancers, to decrease the number of patients who undergo 
unnecessary FNAs, and to enhance user convenience. Established methodological standards and researches 
for developing guidelines have suggested that guideline features should be of high quality, be trustworthy, and 
be implementable21–24. Therefore, it is very surprising that there has been no evidence that proves that thyroid 
nodules 1.5 cm or larger have poorer clinical outcomes compared to nodule smaller than 1.5 cm when focusing 
on nodules 1 cm or larger but smaller than 2 cm. So far, a worldwide consensus on indications for FNA of thy-
roid nodules has not been achieved, making the need for logical evidence more crucial. Our study is the first 
population-based study to demonstrate that there is not enough evidence to support a cutoff tumor size of 1.5 cm 
for managing thyroid nodules after adjusting for patient, tumor, and treatment characteristics although this study 
cannot provide direct evidence for some guidelines which use a cutoff tumor size of 1.5 cm to indicate FNA for 
thyroid nodules.
This study has several strengths. By using the COD variable in the SEER database, we were able to classify 
specific causes of mortality, and were able to perform analyses with an adequate number of deaths occurring 
in thyroid cancer patients. Hence, the SEER database allows us to perform multivariable competing risk anal-
yses adjusting for patient and tumor characteristics, and surgical treatments. The SEER data gave our study, 
a population-based long-term follow-up study, adequate statistical power that could not have been achieved 
by single institution studies. Also, results from a population-based SEER study have more generalizability and 
reliability.
Our study does have several limitations. The SEER database does not include detailed data on comorbidity, 
disease recurrence, and sonographic features which have been included in most FNA guidelines. External val-
idations using well-constructed prospective multi-institutional data for thyroid nodules may provide relevant 
validity for various guidelines. Also, the SEER database might have some coding errors. Before constructing 
the study population, we first excluded patients who were classified as having thyroid cancer but recorded as 
having non-thyroid malignancy as the histological subtype. Information regarding COD in the SEER database 
is acquired from a patient’s death certificate, and there is a chance that this information might be misclassified. 




SDHR (95% CI) P Value SDHR (95% CI) P Value
Tumor size (1.5–1.9 cm vs 1–1.4 cm) 1.55 (1.09 to 2.22) 0.02 0.98 (0.82 to 1.18) 0.85
Age ( ≥ 55 years vs < 55 years) 10.6 (7.18 to 15.8) < 0.001 9.16 (7.56 to 11.1) < 0.001
Male sex 3.42 (2.40 to 4.89) < 0.001 1.97 (1.62 to 2.41) < 0.001
Race
 Black 1.15 (0.44 to 2.96) 0.78 2.74 (1.8 to 4.17) < 0.001
 White 0.99 (0.57 to 1.70) 0.96 1.26 (0.93 to 1.71) < 0.001
 Other Ref. 1 Ref. 1
Histologic subtype
 Other 6.82 (4.25 to 10.94) < 0.001 1.70 (1.12 to 2.6) 0.01
 Follicular 1.82 (0.84 to 3.93) 0.13 1.17 (0.75 to 1.81) 0.49
 Papillary Ref. 1 Ref. 1
Extrathyroidal extension (presence 
vs absence) 8.23 (5.75 to 11.80) < 0.001 1.15 (0.9 to 1.45) 0.26
Cervical lymph node metastasis 
(presence vs absence) 2.16 (1.34 to 3.5) < 0.001 0.98 (0.78 to 1.24) 0.87
Distant metastasis (presence vs 
absence)
16.21 (10.9 to 
24.09) < 0.001 1.51 (0.95 to 2.4) 0.08
Surgery type
 Lobectomy Ref. 1 Ref. 1
 No surgery 7.32 (2.38 to 22.52) < 0.001 8.10 (4.92 to 13.32) < 0.001
 Total thyroidectomy 1.29 (0.74 to 2.24) 0.37 0.66 (0.53 to 0.83) < 0.001
Radiation therapy (presence vs 
absence) 1.34 (0.93 to 1.95) 0.12 0.61 (0.51 to 0.73) < 0.001
Table 4.  Univariable Analyses of Factors Associated with Causes of Death (N = 14117). SDHR, 
subdistribution hazard ratio; CI, confidence interval.
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In summary, we found that having a tumor 1.5 cm or larger in size was not associated with distant metastasis 
and the two causes of death (thyroid cancer mortality and noncancer mortality) after adjustment for patient, 
tumor, and clinical characteristics. Therefore, further studies using the 1.5 cm cutoff as an indication for FNA in 
thyroid nodules are needed.
Methods
SEER Database and Study Population.  The Surveillance, Epidemiology, and End Results (SEER) data-
base covers approximately 30% of the United States population26. We contacted the SEER program of the National 
Cancer Institute in August 2015. Our study only selected cases diagnosed after 1988 because information on 
extent of disease such as lymph node involvement, or detailed information on tumor size was required. 127512 
patients with thyroid cancer (C73.9) as the first primary malignancy as well as histologically diagnosed tumors 
of the thyroid were identified according to the International Classification of Diseases for Oncology, 3rd Edition 
(ICD-O-3).
To include a minimum of 5 years of follow-up survival data, we only selected patients who were diagnosed up 
to 2007. Tumors with sizes equal to or larger than 2 cm or smaller than 1 cm were excluded. We excluded patients 
who were diagnosed with other cancers than thyroid cancer. Patients with no available information on race, sur-
gical findings (extrathyroidal extension, lymph node involvement, surgery type), and radiation therapy were also 
excluded. Patients with a cause of death (COD) record that indicated an unavailable death certificate or patients 
with no records of survival time were excluded. Patients with this data but with no COD recorded (SEER code 
of 41000) were excluded as well. The final study cohort was comprised of 14117 patients with thyroid cancers.
Variables included age at diagnosis (55 years or older vs younger than 55 years), sex, race, extrathyroidal 
extension, cervical lymph node metastasis, distant metastasis, surgery type, and radiotherapy. The presence of 
distant metastasis was determined using the SEER historical staging system. Extent of surgery was grouped as no 
surgery, lobectomy, and total thyroidectomy including subtotal or near-total thyroidectomy.
Thyroid cancer-specific death was ascertained with the SEER COD record of 32010, and noncancer mortality 
was also defined. Survival time was determined from the SEER records on survival time, that is, from date of 
diagnosis to date of last contact. The date of last contact was as follows: for deaths, date of death; for survivors, 
the date of last contact if before December 31, 2012; or December 31, 2012, if date of last contact was after 2012.
Institutional review board approval was not required because data from the SEER program is publically avail-
able and anonymized.
Statistical Analyses.  We divided the patients into two groups, group 1 (nodules 1 cm or larger and smaller 
than 1.5 cm) and group 2 (nodules 1.5 cm or larger and smaller than 2 cm). Patient demographics and clinical 




SDHR (95% CI) P Value SDHR (95% CI) P Value
Tumor size (1.5–1.9 cm vs 
1–1.4 cm) 1.33 (0.91 to 1.96) 0.14 1.04 (0.87 to 1.25) 0.68
Age (≥ 55 years vs < 55 years) 8.77 (5.69 to 13.51) < 0.001 8.65 (7.09 to 10.56) < 0.001
Male sex 2.14 (1.45 to 3.15) < 0.001 1.65 (1.33 to 2.03) < 0.001
Race
 Black 1.49 (0.59 to 3.79) 0.40 2.59 (1.69 to 3.99) < 0.001
 White 1.13 (0.63 to 2.04) 0.68 1.27 (0.94 to 1.73) 0.12
 Other Ref. 1 Ref. 1
Histologic subtype
 Other 4.8 (2.62 to 8.8) < 0.001 0.85 (0.51 to 1.42) 0.53
 Follicular 2.16 (1.05 to 4.45) 0.036 1.05 (0.67 to 1.62) 0.84
Papillary Ref. 1 Ref. 1
Extrathyroidal extension 
(presence vs absence) 5.22 (3.27 to 8.31) < 0.001 1.03 (0.8 to 1.32) 0.84
Cervical lymph node metastasis 
(presence vs absence) 1.96 (1.19 to 3.24) 0.008 1.32 (1.04 to 1.68) .021
Distant metastasis (presence vs 
absence) 6.14 (3.67 to 10.28) < 0.001 1.16 (0.65 to 2.06) 0.62
Surgery type
 Lobectomy Ref. 1 Ref. 1
 No surgery 5.18 (1.87 to 14.36) 0.002 6.19 (3.58 to 10.7) < 0.001
 Total thyroidectomy 1.08 (0.56 to 2.05) 0.83 0.84 (0.66 to 1.07) 0.16
Radiation therapy (presence vs 
absence) 0.98 (0.62 to 1.53) 0.91 0.77 (0.63 to 0.93) 0.008
Table 5.  Multivariable Analyses of Factors Associated with Causes of Death (N = 14117). SDHR, 
subdistribution hazard ratio; CI, confidence interval.
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Univariable and multivariable logistic regression models were used to examine the effects of patient demo-
graphics and clinical characteristics for the presence of distant metastasis. Odds ratios (ORs) and 95% confidence 
intervals (CIs) were estimated.
Cumulative incidence curves for death in the presence of the competing risk were estimated and compared 
between the two groups by Gray’s method27. We used proportional subdistribution hazards regression modeling 
proposed by Fine and Gray to estimate the effects of the covariates on the cumulative probability of specific causes 
of death28. The proportional hazards assumption was assessed graphically with plots of Schoenfeld-type residuals 
against time for each cause of death in the model and by testing the time-dependent covariate for each variable.
The latest American Joint Committee on Cancer (AJCC) staging criteria for differentiated thyroid cancer con-
sider patient age at diagnosis, with 55 years of age being the cutoff value for staging14. Reflecting this guideline, 
we performed separate analyses for both distant metastasis and mortality according to age subgroups using 55 
years as the cutoff.
All tests were two-sided, and a P value of less than.05 was considered statistically significant. Statistical analy-
ses were performed using SAS (version 9.2; SAS Institute Inc, Cary, NC) and R statistical software (version 3.1.1; 
R Foundation, Vienna, Austria). The R package cmprsk was used for competing risks analyses29.
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